Key Highlights
- Vericel Corporation (NASDAQ:VCEL) traded up 20.27% to USD 54.70 in trading on November 5, 2026, per published market data, after third-quarter results and a guidance raise.
- Third-quarter total net Revenue was USD 85.4 million, up 26% from USD 67.5 million, with MACI revenue of USD 67.4 million, up 21%.
- Net income rose 179% to USD 14.2 million, or USD 0.27 per diluted share, and adjusted EBITDA was USD 25.2 million, a 30% margin.
- Full-year revenue guidance rose to USD 344 million to USD 346 million from USD 330 million to USD 340 million, and cash stood at USD 235.6 million with no debt.
Third-Quarter Results and the Raise
Vericel reported third-quarter 2026 results on November 5, 2026, and raised full-year guidance. Total net revenue was USD 85.4 million against USD 67.5 million. MACI, the cartilage repair therapy, contributed USD 67.4 million against USD 55.7 million, and the company reported its highest quarterly MACI Arthro case count since launch. Epicel revenue was USD 12.7 million, up 23%. NexoBrid delivered USD 2.3 million of commercial revenue plus USD 3.0 million of procurement revenue from the Biomedical Advanced Research and Development Authority. Burn Care revenue was USD 18.0 million, up 52%. Year-to-date revenue was USD 231.3 million, up 26%, and year-to-date MACI revenue was USD 189.3 million, up 22%, so the quarter extended an established trend rather than marking a one-off jump.
Margins, Guidance and Management View
Gross Margin was 73%, level with the prior-year quarter. Net Income was USD 14.2 million against USD 5.1 million, and adjusted EBITDA was USD 25.2 million against USD 17.0 million, lifting the margin to 30% from 25% as revenue growth spread over a mostly Fixed Cost base, the usual Operating Leverage in a specialty Biologics company. New 2026 guidance calls for total revenue of USD 344 million to USD 346 million, MACI revenue of USD 290 million to USD 292 million, up from USD 284 million to USD 290 million, Burn Care revenue of USD 54 million against USD 46 million to USD 50 million, and an adjusted EBITDA margin of 28% against 27%. Gross margin guidance of about 75% was reaffirmed, and year-to-date adjusted EBITDA of USD 49.6 million was up 48%. President and Chief Executive Nick Colangelo said Vericel is well positioned for a strong close to 2026.
Risks and What to Watch
Published market data lists a market Capitalization near USD 2.8 billion and trailing diluted EPS of USD 0.46, implying a price-to-earnings multiple of about 118, so expectations are high. Vericel depends heavily on MACI, which carried about four fifths of third-quarter revenue on simple arithmetic, and on surgeon adoption of the arthroscopic format. Reimbursement, Manufacturing capacity and BARDA contract timing for NexoBrid can shift results between quarters. Trading Volume was about 378,000 shares, below average, and a quoted intraday gain of 20.27% can partly reverse. Management expects to sustain this momentum in 2027 and beyond, a claim the market will test through fourth-quarter MACI growth, the Burn Care ramp, the pace of MACI Arthro adoption among surgeons and any early 2027 commentary on margins and spending.
Where Things Stand
The climb at Vericel Corporation (NASDAQ:VCEL) looks earned on the numbers: revenue grew 26%, profit nearly tripled, every major guidance line moved up and the Balance Sheet holds USD 235.6 million of cash with no debt. The open question is valuation rather than operations, since a multiple near 118 on trailing Earnings leaves little room for a miss. Fourth-quarter MACI and Burn Care delivery against the new range is the next test, followed by management's first 2027 framework.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...